A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Summary

A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC).

Timeline

Start

2021-07-28

Primary completion

2023-04-18

Completion

2023-04-18

Outcome

Outcome not reported

Stopped: “Adverse change in the risk/benefit.”

Drugs

Indications